Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation

Peroxisome proliferator-activated receptor γ (PPARγ) is a major therapeutic target for the treatment of type 2 diabetes. However, the use of PPARγ-targeted drugs, such as rosiglitazone and pioglitazone, is limited owing to serious side effects caused by classical agonism. Using a rational drug disco...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Jun Young, Kim, Hyunsoo, Kim, Hyun-Jung, Suh, Se Won, Park, Seung Bum, Han, Byung Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6671948/
https://www.ncbi.nlm.nih.gov/pubmed/31371757
http://dx.doi.org/10.1038/s41598-019-47672-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6671948/
https://www.ncbi.nlm.nih.gov/pubmed/31371757
http://dx.doi.org/10.1038/s41598-019-47672-w

Ejemplares similares